AstraZeneca

11 pages

Health Nasal version of the Oxford/AstraZeneca COVID vaccine fails in U.K. trial
BYSophie Mellor
October 11, 2022
Health Top AstraZeneca heart drug Farxiga sees potential to reach more patients
BYBloomberg
August 27, 2022
Health The most innovative and inventive drug companies of 2022 set the foundation for success before the pandemic
BYSy Mukherjee and IDEA Pharma
April 20, 2022
Health New drug that prevents you from catching COVID-19 gets green light in Europe — but it’s been in the U.S. for months and hardly anyone knows about it
BYSophie Mellor
March 29, 2022
Finance Omicron is upping booster jab demand. So why are COVID vaccine makers’ shares tanking?
BYJeremy Kahn
December 29, 2021
Health Moderna hit by shareholders who want to know why its COVID-19 vaccine is so expensive and unavailable in poorer countries
BYDavid Meyer
December 27, 2021

Health AstraZeneca finds its COVID booster delivers adequate protection against Omicron
BYSuzi Ring and Bloomberg
December 23, 2021
Health AstraZeneca COVID-19 vaccine’s protection against severe illness fades quickly, study finds
BYJeremy Kahn
December 21, 2021
Health EU bulks up its arsenal against Omicron with approval of Novavax vaccine. Investors dump shares
BYChristiaan Hetzner
December 20, 2021
Health J&J, Sputnik, and Sinopharm vaccines found to be largely ineffective in fighting Omicron: study
BYBloomberg
December 17, 2021
International Omicron is making scientists redefine what it means to be ‘fully vaccinated’ against COVID
BYSophie Mellor
December 13, 2021
Health Global drugmakers could roll out Omicron-adapted COVID vaccines in 100 days
BYYvonne Lau
November 29, 2021
Health Pfizer’s COVID-19 vaccine generated the strongest immune response in study of 4 jabs
BYJason Gale and Bloomberg
November 15, 2021
Health AstraZeneca shifts away from nonprofit model for its COVID-19 vaccine, except when selling to poor countries
BYDavid Meyer
November 12, 2021
International What happens when COVID jabs begin to wane? The U.K. offers up a painful lesson
BYSophie Mellor
October 22, 2021

Most Popular

Retail
Cannabis chain once worth $1.7 billion and called the ‘Apple store of weed’ is now nearly failing as the once-hot pot...
February 7, 2023
BYVerne Kopytoff
Success
‘Resenteeism’ is the latest trend plaguing workers, and it’s even more dangerous than quiet quitting
February 6, 2023
BYJane Thier
Finance
Goldman Sachs makes a bold housing market call
February 6, 2023
BYLance Lambert

1 - 15 of 164 results

...